Integrative Genomics, Epigenomics and Bioinformatics Analyses of Human Uterine Fibroids

子宫肌瘤(UL)，也被称为子宫肌瘤，是一种良性的平滑肌肿瘤， 细胞外基质蛋白的沉积。UL是世界范围内的一个主要健康问题，因为它影响到几乎 70%-80%的女性和不成比例的非裔美国人，但仍然鲜为人知。《长河》 我们团队的学期目标是系统地发现调节关键分子事件的新机制 会导致子宫肌瘤。这个R01应用程序的直接目标是测试更改后的假设 表观基因组特征定义了正常的子宫肌层组织和肌瘤，以及治疗过的人类组织。 利用全基因组研究结合生物信息学和其他分析，我们将确定表观基因组 首次出现子宫纤维化的征兆。这项不偏不倚的研究将确定表观基因组的分化 正常和病变组织的特征，并可能允许外照射疗法的发展(针对 表观基因组)治疗肌瘤 这项拟议的工作具有科学、翻译和临床意义，具有很高的创新性。 因为这代表了对肌瘤表观基因组的首次系统研究。从以下方面获得的结果 这一分析将被用来产生新的假设，以更好地理解 肌瘤。

Uterine leiomyomas (UL), also known as uterine fibroids, are benign smooth muscle tumors with excessive depostition of extracellular matrix proteins. UL is a major health problem worldwide, because it affects almost 70-80% of all women and disproportionally African Americans, but still remains poorly understood. The long term goal of our team is to systematically discover novel mechanisms regulating key molecular events that contribute to leiomyoma. The immediate goal of this R01 application is to test the hypothesis that altered epigenomic signatures define normal myometrial tissues and leiomyomas, and therapy treated human tissues. Using genome-wide studies integrated with bioinformatic and other analyses, we will determine the epigenomic signatures in uterine fibrosis for the first time. This unbiased study will identify epigenomic differentiating features of normal and diseased tissues and may allow for development of Epitherapy (targeting the epigenome) for leiomyomas The proposed work is scientifically, translationally, and clinically significant and highly innovative because it represents the first systematic exploration of the epigenome in leiomyomas. Results obtained from this analysis will be used to generate new hypotheses to better understand the molecular underpinning of leiomyomas.